<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609853</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00085652</org_study_id>
    <secondary_id>R01DA043475</secondary_id>
    <nct_id>NCT03609853</nct_id>
  </id_info>
  <brief_title>Behavioral Pharmacology of THC and D-limonene</brief_title>
  <official_title>Behavioral Pharmacology of THC and D-limonene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized d-limonene&#xD;
      and THC administered via inhalation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research&#xD;
      Unit (BPRU). Participants will complete 9 acute drug administration periods in which they&#xD;
      will administer THC alone, limonene alone, THC and limonene together, or placebo. Subjective&#xD;
      drug effects and vital signs will be assessed following drug administration. Each participant&#xD;
      will receive all 9 dose conditions in a randomized order using a placebo controlled&#xD;
      within-subject crossover design. The study will help us understand the individual and&#xD;
      interactive effects of THC and d-limonene, two common constituents found in cannabis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>placebo controlled, double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Anxiety as assessed by the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak rating (0-100) of Anxiety on the DEQ, a visual analog scale (VAS) self-report questionnaire with 0 being No anxiety and 100 being maximum anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Unpleasant Effect as assessed by the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak rating (0-100) of Unpleasant Effect on the DEQ, with 0 being no unpleasant effect and 100 being worst unpleasant effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty in Performing Routine Tasks as assessed the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak rating (0-100) of Difficulty Performing Routine Tasks on the DEQ, 0 being no difficulty and 100 being inability to perform task all together</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak change from baseline in Heart Rate (bpm) measured in seated position by automated monitor</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>D-limonene and THC Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (5mL distilled water)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized low THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of pure THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized high THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of pure THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized low d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized high d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low THC and low d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of THC paired with 1mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High THC and low d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of THC paired with 1mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low THC and high d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of THC paired with 5mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High THC and high d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of THC paired with 5mg of d-limonene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo vapor (distilled water)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaporized THC, limonene, or THC and limonene</intervention_name>
    <description>Acute drug exposure</description>
    <arm_group_label>High THC and high d-limonene</arm_group_label>
    <arm_group_label>High THC and low d-limonene</arm_group_label>
    <arm_group_label>Low THC and high d-limonene</arm_group_label>
    <arm_group_label>Low THC and low d-limonene</arm_group_label>
    <arm_group_label>Vaporized high THC</arm_group_label>
    <arm_group_label>Vaporized high d-limonene</arm_group_label>
    <arm_group_label>Vaporized low THC</arm_group_label>
    <arm_group_label>Vaporized low d-limonene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have provided written informed consent&#xD;
&#xD;
          2. Be between the ages of 18 and 55&#xD;
&#xD;
          3. Be in good general health based on a physical examination, medical history, vital&#xD;
             signs, 12-lead ECG and screening urine and blood tests&#xD;
&#xD;
          4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the&#xD;
             screening visit and at clinic admission&#xD;
&#xD;
          5. Not be pregnant or nursing (if female). All females must have a negative serum&#xD;
             pregnancy test at the screening visit and a negative urine pregnancy test at clinic&#xD;
             admission.&#xD;
&#xD;
          6. Have a body mass index (BMI) in the range of 18 to 36 kg/m2&#xD;
&#xD;
          7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of&#xD;
             150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg&#xD;
&#xD;
          8. Have no allergies to any of the ingredients used to prepare vapor (THC, d-limonene).&#xD;
&#xD;
          9. Report having experienced anxiety after consuming cannabis in the past.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3&#xD;
             month prior to the Screening Visit;&#xD;
&#xD;
          2. History of or current evidence of significant medical (e.g. seizure disorder) or&#xD;
             psychiatric illness (e.g. psychosis) judged by the investigator to put the participant&#xD;
             at greater risk of experiencing an adverse event due to exposure or completion of&#xD;
             other study procedures.&#xD;
&#xD;
          3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within&#xD;
             14 days of experimental sessions; which, in the opinion of the investigator or&#xD;
             sponsor, will interfere with the study result or the safety of the subject.&#xD;
&#xD;
          4. Use of a prescription medication (with the exception of birth control prescriptions)&#xD;
             within 14 days of experimental sessions; which, in the opinion of the investigator or&#xD;
             sponsor, will interfere with the study result or the safety of the subject.&#xD;
&#xD;
          5. Use of dronabinol (MarinolÂ®) within the past month.&#xD;
&#xD;
          6. Average use of cannabis more than 2 times per week in the prior 3 months.&#xD;
&#xD;
          7. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g.,&#xD;
             Prinzmetal's angina).&#xD;
&#xD;
          8. Abnormal EKG result that in the investigator's opinion is clinically significant.&#xD;
&#xD;
          9. Enrolled in another clinical trial or have received any drug as part of a research&#xD;
             study within 30 days prior to dosing.&#xD;
&#xD;
         10. Having previously sought medical attention to manage adverse effects following acute&#xD;
             cannabis use.&#xD;
&#xD;
         11. Individuals with anemia or who have donated blood in the prior 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua Elmore</last_name>
    <phone>410-550-9491</phone>
    <email>jelmore4@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Vandrey</last_name>
    </contact>
    <investigator>
      <last_name>Ryan Vandrey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

